| Source: |
| Type: |
| Hypoxia-Inducible-Factor 1A (HIF1A gene, HIF1α, HIF-1α protein product) -Dominantly expressed under hypoxia(low oxygen levels) in solid tumor cells -HIF1A induces the expression of vascular endothelial growth factor (VEGF) -High HIF-1α expression is associated with Poor prognosis -Low HIF-1α expression is associated with Better prognosis -Functionally, HIF-1α is reported to regulate glycolysis, whilst HIF-2α regulates genes associated with lipoprotein metabolism. -Cancer cells produce HIF in response to hypoxia in order to generate more VEGF that promote angiogenesis Key mediators of aerobic glycolysis regulated by HIF-1α. -GLUT-1 → regulation of the flux of glucose into cells. -HK2 → catalysis of the first step of glucose metabolism. -PKM2 → regulation of rate-limiting step of glycolysis. -Phosphorylation of PDH complex by PDK → blockage of OXPHOS and promotion of aerobic glycolysis. -LDH (LDHA): Rapid ATP production, conversion of pyruvate to lactate; HIF-1α Inhibitors: -Curcumin: disruption of signaling pathways that stabilize HIF-1α (ie downregulate). -Resveratrol: downregulate HIF-1α protein accumulation under hypoxic conditions. -EGCG: modulation of upstream signaling pathways, leading to decreased HIF-1α activity. -Emodin: reduce HIF-1α expression. (under hypoxia). -Apigenin: inhibit HIF-1α accumulation. |
| 2298- | Ba, | Flavonoids Targeting HIF-1: Implications on Cancer Metabolism |
| - | Review, | Var, | NA |
| 2290- | Ba, | Research Progress of Scutellaria baicalensis in the Treatment of Gastrointestinal Cancer |
| - | Review, | GI, | NA |
| 2291- | Ba, | BA, | Baicalein and Baicalin Promote Melanoma Apoptosis and Senescence via Metabolic Inhibition |
| - | in-vitro, | Melanoma, | SK-MEL-28 | - | in-vitro, | Melanoma, | A375 |
| 2391- | Ba, | Scutellaria baicalensis and its flavonoids in the treatment of digestive system tumors |
| - | Review, | GC, | NA |
| 1392- | BBR, | Based on network pharmacology and experimental validation, berberine can inhibit the progression of gastric cancer by modulating oxidative stress |
| - | in-vitro, | GC, | AGS | - | in-vitro, | GC, | MKN45 |
| 1399- | BBR, | Rad, | Radiotherapy Enhancing and Radioprotective Properties of Berberine: A Systematic Review |
| - | Review, | NA, | NA |
| - | Trial, | BC, | NA |
| 2708- | BBR, | Berberine decelerates glucose metabolism via suppression of mTOR‑dependent HIF‑1α protein synthesis in colon cancer cells |
| - | in-vitro, | CRC, | HCT116 |
| 2709- | BBR, | Berberine inhibits the glycolysis and proliferation of hepatocellular carcinoma cells by down-regulating HIF-1α |
| - | in-vitro, | HCC, | HepG2 |
| 2686- | BBR, | Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs |
| - | Review, | Nor, | NA |
| 956- | BBR, | Berberine inhibits HIF-1alpha expression via enhanced proteolysis |
| - | in-vitro, | Nor, | HUVECs | - | in-vitro, | GC, | SCM1 |
| 5179- | BBR, | Regulation of Cell Signaling Pathways by Berberine in Different Cancers: Searching for Missing Pieces of an Incomplete Jig-Saw Puzzle for an Effective Cancer Therapy |
| - | Review, | Var, | NA |
| 5180- | BBR, | Berberine Targets AP-2/hTERT, NF-κB/COX-2, HIF-1α/VEGF and Cytochrome-c/Caspase Signaling to Suppress Human Cancer Cell Growth |
| - | in-vitro, | NSCLC, | NA |
| 5633- | BCA, | Mechanisms Behind the Pharmacological Application of Biochanin-A: A review |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 5586- | BetA, | Suppression of HIF-1α accumulation by betulinic acid through proteasome activation in hypoxic cervical cancer |
| - | in-vitro, | Cerv, | HeLa |
| 2729- | BetA, | Betulinic acid in the treatment of tumour diseases: Application and research progress |
| - | Review, | Var, | NA |
| 2731- | BetA, | Betulinic Acid for Glioblastoma Treatment: Reality, Challenges and Perspectives |
| - | Review, | GBM, | NA | - | Review, | Park, | NA | - | Review, | AD, | NA |
| 2738- | BetA, | Betulinic Acid Suppresses Breast Cancer Metastasis by Targeting GRP78-Mediated Glycolysis and ER Stress Apoptotic Pathway |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | BT549 | - | in-vivo, | NA, | NA |
| 2766- | BetA, | Role of natural secondary metabolites as HIF-1 inhibitors in cancer therapy |
| - | Review, | Var, | NA |
| 5686- | BJ, | BRU, | A review of Brucea javanica: metabolites, pharmacology and clinical application |
| - | Review, | Var, | NA |
| 5689- | BJ, | Brucea javanica oil inhibited the proliferation, migration, and invasion of oral squamous carcinoma by regulated the MTFR2 pathway |
| - | vitro+vivo, | Oral, | CAL27 |
| 5652- | BNL, | Borneol promotes apoptosis of Human Glioma Cells through regulating HIF-1a expression via mTORC1/eIF4E pathway |
| - | vitro+vivo, | GBM, | NA |
| 5662- | BNL, | Rad, | Role of Borneol Induced Autophagy in Enhancing Radiosensitivity of Malignant Glioma |
| - | vitro+vivo, | GBM, | NA |
| 5668- | BNL, | Anticancer effect of borneol: Mechanistic insights through literature review and in silico studies |
| - | Review, | Var, | NA |
| 5673- | Bor, | Calcium Fructoborate Prevents Skin Cancer Development in Balb-c Mice |
| - | in-vivo, | Nor, | NA |
| 3522- | Bor, | The Boron Advantage: The Evolution and Diversification of Boron’s Applications in Medicinal Chemistry |
| - | Review, | Var, | NA |
| 715- | Bor, | Boron-containing phenoxyacetanilide derivatives as hypoxia-inducible factor (HIF)-1alpha inhibitors |
| - | in-vitro, | Pca, | HeLa |
| 5697- | BRU, | Brusatol, a Nrf2 Inhibitor Targets STAT3 Signaling Cascade in Head and Neck Squamous Cell Carcinoma |
| - | in-vitro, | HNSCC, | NA |
| 5699- | BRU, | BJ, | Identification of the Brucea javanica Constituent Brusatol as a EGFR-Tyrosine Kinase Inhibitor in a Cell-Free Assay |
| - | in-vitro, | Lung, | A549 |
| 1652- | CA, | Caffeic Acid and Diseases—Mechanisms of Action |
| - | Review, | Var, | NA |
| - | in-vitro, | Cerv, | SiHa |
| 5842- | CAP, | Capsaicin: Current Understanding of Its Mechanisms and Therapy of Pain and Other Pre-Clinical and Clinical Uses |
| - | Review, | Nor, | NA | - | Review, | Diabetic, | NA |
| 1259- | CAP, | Capsaicin inhibits HIF-1α accumulation through suppression of mitochondrial respiration in lung cancer cells |
| - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H23 | - | in-vitro, | Lung, | H2009 |
| 5893- | CAR, | TV, | Thymol and Carvacrol: Molecular Mechanisms, Therapeutic Potential, and Synergy With Conventional Therapies in Cancer Management |
| - | Review, | Var, | NA |
| 5892- | CAR, | SRF, | Carvacrol potentiates immunity and sorafenib anti-cancer efficacy by targeting HIF-1α/STAT3/ FGL1 pathway: in silico and in vivo study |
| - | in-vivo, | HCC, | NA |
| 1103- | CBD, | Cannabidiol inhibits invasion and metastasis in colorectal cancer cells by reversing epithelial-mesenchymal transition through the Wnt/β-catenin signaling pathway |
| - | vitro+vivo, | NA, | NA |
| 955- | CEL, | Celecoxib Down-Regulates the Hypoxia-Induced Expression of HIF-1α and VEGF Through the PI3K/AKT Pathway in Retinal Pigment Epithelial Cells |
| - | in-vitro, | RPE, | D407 |
| 5943- | Cela, | Celastrol: A Spectrum of Treatment Opportunities in Chronic Diseases |
| - | Review, | Arthritis, | NA | - | Review, | IBD, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 2653- | Cela, | Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence |
| - | Review, | Var, | NA |
| 6002- | CGA, | Chlorogenic Acid: A Systematic Review on the Biological Functions, Mechanistic Actions, and Therapeutic Potentials |
| - | Review, | Var, | NA | - | Review, | Diabetic, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | Stroke, | NA |
| 6009- | CGA, | Chlorogenic Acid: An In-Depth Review of Its Effectiveness in Cancer Treatment |
| - | Review, | Var, | NA |
| 6026- | CGA, | Chlorogenic Acid: The Conceivable Chemosensitizer Leading to Cancer Growth Suppression |
| - | Review, | Var, | NA |
| 954- | CGA, | Chlorogenic acid inhibits hypoxia-induced angiogenesis via down-regulation of the HIF-1α/AKT pathway |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | HUVECs |
| 2802- | CHr, | Chrysin inhibits expression of hypoxia-inducible factor-1alpha through reducing hypoxia-inducible factor-1alpha stability and inhibiting its protein synthesis |
| - | in-vitro, | Pca, | DU145 | - | in-vivo, | Pca, | NA |
| 2785- | CHr, | Emerging cellular and molecular mechanisms underlying anticancer indications of chrysin |
| - | Review, | Var, | NA |
| 2786- | CHr, | Chemopreventive and therapeutic potential of chrysin in cancer: mechanistic perspectives |
| - | Review, | Var, | NA |
| 2788- | CHr, | Chrysin: Sources, beneficial pharmacological activities, and molecular mechanism of action |
| - | Review, | Var, | NA |
| 953- | CHr, | Inhibition of Hypoxia-Inducible Factor-1α and Vascular Endothelial Growth Factor by Chrysin in a Rat Model of Choroidal Neovascularization |
| - | in-vivo, | NA, | NA |
| 1568- | Cin, | Can Cinnamon be the Silver Bullet for Cancer? |
| - | Review, | NA, | NA |
| - | Review, | AD, | NA | - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:143 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid